# Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

> **NCT03016819** · PHASE3 · RECRUITING · sponsor: **Advenchen Laboratories, LLC** · enrollment: 325 (estimated)

## Conditions studied

- Alveolar Soft Part Sarcoma
- Leiomyosarcoma
- Synovial Sarcoma
- Soft-Tissue Sarcoma

## Interventions

- **DRUG:** AL3818
- **DRUG:** Dacarbazine
- **DRUG:** AL3818 or placebo
- **DRUG:** Midazolam 2 mg for CYP3A4 phenotyping
- **DRUG:** Digoxin (0.25mg)
- **DRUG:** Rosuvastatin 10 mg tablet.

## Key facts

- **NCT ID:** NCT03016819
- **Lead sponsor:** Advenchen Laboratories, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-08-15
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 325 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03016819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03016819, "Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03016819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*